Risk Based Monitoring

Immune-Onc Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients With Advanced Solid Tumors


– Multicenter Phase 1 study to evaluate IO-108 as monotherapy and in combination with an anti-PD-1 – – IO-108 is Company’s second program to advance to clinic – Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints, today announced that…

Read More

How To Combine Quality Management With Risk-Based Monitoring In Clinical Trials


Meaghan Powers, lead consultant, Halloran Consulting Group penned an excellent article on integrating Quality Management with RBM Meaghan tackles a number topics in the 3 Key Steps To Successful Execution. First, a risk assessment must be conducted both pre-study and ongoing during the trial. Second, a well-articulated study protocol should be developed based on factors…

Read More